About: A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 July 1997

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 1997 (uk) im Juli 1997 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunetu de 1997 (ast) scientific article published on 01 July 1997 (en)
publication date	wds:Q73526630-29E646C9-6371-48C8-AAB4-2BC2859A0D6C
publication date	1997-07-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q73526630-8FB50B20-6730-4BCB-94C6-B6AEF6AFEB58
author name string	Gallo JM
rdfs:label	A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva (en) A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva (nl)
skos:prefLabel	A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva (en) A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva (nl)
name	A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva (en) A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva (nl)
author	wds:Q73526630-4CA1A889-3DFF-40ED-AE4B-E6FBA27588E9
author	Urs O. Häfeli
title	wds:Q73526630-756DC610-1589-4B58-95AF-EFF8352A0E5A
title	A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res., 56: 4686-4693, 1996 (en)
page(s)	wds:Q73526630-E28D2C21-DD73-4A38-9EA5-85E9AB006FD6
page(s)	3063-3065
instance of	wds:Q73526630-7A223F52-27B3-4145-88DA-A35E8F23E4E4
instance of	scholarly article
PubMed ID	wds:Q73526630-506EE4D8-AC1F-4F8C-A6F6-A8B6A69351E6
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9230223
PubMed ID	9230223
published in	wds:Q73526630-ED6B03B0-0729-43AC-838D-0315C23D8ADA
published in	Cancer Research
issue	wds:Q73526630-74268417-3DFE-432A-BC53-E9701101116C
volume	wds:Q73526630-6392C61C-35FD-46C2-A694-3EFAD508D05E
issue	14
volume	57
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73526630
is cites work of	Evaluation of magnetic micro- and nanoparticle toxicity to ocular tissues Magnetic nanoparticles in MR imaging and drug delivery. Process and formulation variables in the preparation of injectable and biodegradable magnetic microspheres Nanoparticle-based theranostic agents Citric-acid-coated magnetite nanoparticles for biological applications. Magnetic nanoparticle drug carriers and their study by quadrupole magnetic field-flow fractionation Fe3O4-solamargine induces apoptosis and inhibits metastasis of pancreatic cancer cells
is cites work of	wds:Q37376480-942C2338-851F-4822-BF3D-2320A4770ACD wds:Q30498930-A36621DB-8D7D-42A4-89B4-E0804B6B8971 wds:Q37192908-03B88B06-6801-447F-A327-9FB217B9A3D6 wds:Q93357327-75CA0C2E-DA96-430B-AEE6-0ECDDDADD544 wds:Q33920796-BFE9E879-D8DD-4BEC-AC8F-8D5FDEBA064B wds:Q34130095-26DAF253-07E5-42B8-B213-C5E05A819CD6 wds:Q51092592-14475A23-94A1-4018-BF20-F2B1E0A2D6E3

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software